• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE 4.55% $1.05

RECCE PHARMACEUTICALS LTD - Corporate Spotlight

An Emerging Global Leader in the New Generation of Antibiotic Therapies Recce... An Emerging Global Leader in the New Generation of Antibiotic Therapies Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Antibiotic Therapies

Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics.
View the full Corporate Spotlight arrow Created with Sketch.

Interview with James Graham, Executive Director

RCE APPROVAL TO START BURNS STUDY

arrow-down-2 Created with Sketch.

Recce Pharmaceuticals (ASX:RCE) gains ethics approval to start burns study

Health Care

ASX:RCE    

Recce Pharmaceuticals (ASX:RCE) - Non Executive Chairman, John Prendergast - The Market Herald

Non Executive Chairman, John Prendergast
Source: Recce Pharmaceuticals


  • Recce Parmaceuticals (RCE) has been granted ethics approval to start a phase one/two study on patients with infected burn wounds
  • The trial will test a spray-on formulation of candidate drug, RECCE 327, which is a broad-spectrum synthetic polymer antibiotic
  • Recce anticipates the study will be sponsored by WA's South Metropolitan Health Service, with Fiona Stanley Hospital nominated as the study site
  • A previously announced intravenous study will run in parallel to demonstrate the broad administration capabilities of RECCE 327
  • Recce 327 is being developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms
  • Recce Pharmaceuticals is trading 4.72 per cent higher for $1.11




Recce Parmaceuticals (RCE) has been granted ethics approval to start a phase one/two study on patients with infected burn wounds.


The trial will test the company's drug candidate, RECCE 327, which is a broad-spectrum synthetic polymer antibiotic. 


The trial

The study will assess the safety and efficacy of RECCE 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two weeks.


10 patients will receive the drug daily, while a further 20 will receive treatment three times per week.


Recce anticipates the study will be sponsored by WA's South Metropolitan Health Service, with Fiona Stanley Hospital nominated as the study site.


Investigators will review the study data for clinical efficacy and toxicity before deciding to expand the trial to phase two to test the compound against the current best standards of care.


The drug will be delivered via a specially developed spray-on formulation, which was manufactured at Recce's facility. 


Outlook

A previously announced intravenous study will run in parallel to demonstrate the broad administration capabilities of RECCE 327.

Recce Pharmaceuticals Chairman Dr John Prendergast says gaining Human Research Ethics Committee (HREC) approval is an important step.


"Human ethics approval is another milestone for Recce and the clinicians seeking effective treatments to combat the scourge of antibiotic resistant bacteria," the Chairman said.


"Achieving this goal speaks to the dedication of our clinical and research team as we continue to build on our clinical and commercial potential," he concluded.


Recce 327 is being developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria — including their superbug forms.


The company is working towards developing new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.


Recce Pharmaceuticals is trading 4.72 per cent higher for $1.11 at 10:43 am AEDT.



Read the full article on The Market Herald Here

ABOUT US

arrow-down-2 Created with Sketch.

ABOUT US


An Emerging Global Leader in the New Generation of Anti-Infective Therapies


Recce Pharmaceuticals Ltd (ASX: RCE) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens. 


RECCE® 327 and RECCE® 529 have been designed with a unique mechanism of action, with the goal of re-empowering physicians in their potential of an effective treatment that may be used repeatedly against a broad range of bacteria and viruses. RECCE® 529 is a new synthetic polymer formulation with indication against viruses.


Preclinical studies of RECCE® 327 indicates a fast acting, broad-spectrum antibiotic effective against Gram-positive and Gram-negative bacteria, including antibiotic resistant superbugs.


In 2017 RECCE® 327 was awarded Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval.


Recce Origin

Recce Pharmaceuticals was founded by Dr. Graham Melrose, a former Executive Director, and Head of Research at Johnson & Johnson Asia Pacific and Australia. Following his discovery of RECCE® 327 and RECCE® 529, Recce Pharmaceuticals has since expanded to include a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by bacterial and viral pathogens.


Recce (pronounced Re-Key) originates from the military term ‘Reconnaissance’ as a military tactic – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.


We have adopted this approach to anti-infectives, where they are designed to:

  1.  Enter the human body,
  2.  Find the infection and threat (deadly bacteria and viruses),
  3.  Eliminate the threat
  4.  Exit without being noticed (side effects)




Our Vision & Values

“To target the global health problem of superbugs”




Discover

New synthetic (polymer based) drugs are uniquely used for targeting major human health threats. With over 30 years of polymer experience, Dr Melrose and team are well placed to broaden Recce’s technical capabilities.



Patent

Patents are the value of any technology company and Recce Pharmaceuticals Ltd is no exception. With a track record of applying for a patent and it always being accepted, Recce is well positioned to continue expanding its wholly owned international patent portfolio.




Commercialise

As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is funded to pursue its drug development activities, starting with the world’s largest pharmaceutical market the USA – as regulated by the with the U.S. Food and Drug Administration. Recce’s capitalistic culture sees all technical endeavours focused around a commercial outcome.



VIDEOS

arrow-down-2 Created with Sketch.


Interview with James Graham, Executive Director - Recee Pharmaceuticals 




(20min delay)
Last
$1.05
Change
-0.050(4.55%)
Mkt cap ! $182.3M
Open High Low Value Volume
$1.09 $1.09 $1.05 $477.4K 449.5K

Buyers (Bids)

No. Vol. Price($)
20 93745 $1.05
 

Sellers (Offers)

Price($) Vol. No.
$1.08 42 1
View Market Depth
Last trade - 16.10pm 23/10/2020 (20 minute delay) ?
(live)
Last
$1.07
  Change
-0.050 ( 1.10 %)
Open High Low Volume
$1.08 $1.08 $1.05 38294
Last updated 15.59pm 23/10/2020 (live) ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.